• Markets
    • icon
  • Companies
ATX · ASX

Amplia Therapeutics Ltd. (ASX:ATX)

AU$0.068

 0.0 (0.0%)
ASX:Live
06/12/2023 12:50:16 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ATX Overview

ATX Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ATX

Website

Amplia Therapeutics Ltd.

Telephone

61.2.8003.3650

Address

Level 17 350 Queen Street Melbourne, Victoria (VIC) 3000

Description

Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded on May 31, 2000 and is headquartered in Melbourne, Australia.

ATX Price Chart

Key Stats

Market Cap

AU$14.36M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.06 - 0.12

Trade Value (12mth)

AU$1,789.00

1 week

-9.33%

1 month

-13.92%

YTD

-17.07%

1 year

-20%

All time high

16.7493

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

194m

HALO Sector

Healthcare

Next Company Report Date

27-May-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ATX Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 May 23

Key to Corporate Governance Disclosures

×

Key to Corporate Governance Disclosures

31 July 23

ATX Quarterly Activities and Cashflow Reports - June 23 Qtr

×

ATX Quarterly Activities and Cashflow Reports - June 23 Qtr

31 July 20

Annual Report to Shareholders - YE 31 March 2020

×

Annual Report to Shareholders - YE 31 March 2020

31 August 22

Amplia Receives $1.8m R&D Tax Incentive

×

Amplia Receives $1.8m R&D Tax Incentive

30 October 23

Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer

×

Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer

30 May 23

Annual Report to Shareholders

×

Annual Report to Shareholders

30 May 23

2023 Corporate Governance Statement

×

2023 Corporate Governance Statement

30 May 22

Preliminary Final Report and Annual Report YE 31 March 2022

×

Preliminary Final Report and Annual Report YE 31 March 2022

30 May 22

2022 Corporate Governance Statement

×

2022 Corporate Governance Statement

30 May 22

App 4G - Key to Corporate Governance Disclosures

×

App 4G - Key to Corporate Governance Disclosures

30 June 22

Application for quotation of securities - ATX

×

Application for quotation of securities - ATX

30 January 23

Quarterly Activities and Cashflow Reports - December 2022

×

Quarterly Activities and Cashflow Reports - December 2022

30 August 19

Results of Annual General Meeting

×

Results of Annual General Meeting

29 September 23

AACR Pancreatic Cancer Conference Presentation

×

AACR Pancreatic Cancer Conference Presentation

29 November 22

ACCENT Trial Recruitment Progress

×

ACCENT Trial Recruitment Progress

29 May 23

AMP945 and FOLFIRINOX active in model of Pancreatic Cancer

×

AMP945 and FOLFIRINOX active in model of Pancreatic Cancer

29 June 22

Annual General Meeting to be held Thursday 25 August 2022

×

Annual General Meeting to be held Thursday 25 August 2022

29 August 23

Notification regarding unquoted securities - ATX

×

Notification regarding unquoted securities - ATX

29 August 23

Change of Director's Interest Notice - Dr Christopher Burns

×

Change of Director's Interest Notice - Dr Christopher Burns

28 September 21

Proactive Investors Lifesciences Webinar Presentation

×

Proactive Investors Lifesciences Webinar Presentation

28 October 22

Quarterly Activities and Cashflow Reports - Sep 2022 Qtr

×

Quarterly Activities and Cashflow Reports - Sep 2022 Qtr

28 July 22

Quarterly Activities and Cashflow Reports - June 2022 Qtr

×

Quarterly Activities and Cashflow Reports - June 2022 Qtr

28 July 21

Quarterly Activities and Cashflow Reports and Presentation

×

Quarterly Activities and Cashflow Reports and Presentation

28 February 23

ACCENT Trial Recruitment Progress

×

ACCENT Trial Recruitment Progress

27 September 21

Amplia to Present at Proactive Investor Lifesciences Webinar

×

Amplia to Present at Proactive Investor Lifesciences Webinar

27 August 21

AGM - Chief Executive Officer's Presentatioin

×

AGM - Chief Executive Officer's Presentatioin

ATX Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.02 N/A Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.02 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 43.2 -5.0 N/A Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.02 N/A Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.3 -4.6 N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock -11.9 -20.9 N/A Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.09 0.11 N/A Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.07 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 139.4 226.0 N/A Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 96 146 N/A Lock Lock Lock
Basic m Lock Lock Lock Lock 96 146 N/A Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 6 N/A Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.1 -377.5 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -6 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.6 -45.2 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -6 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.5 -45.2 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -4 -6 N/A Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 N/A Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -4 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -2.8 -59.8 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -4 N/A Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 4 17 N/A Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -4 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -39.9 -51.2 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 15 N/A Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 11 24 N/A Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 2 N/A Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -13 N/A Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 3 N/A Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 22 N/A Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 24 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.2 131.6 N/A Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.0 -14.9 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.1 -16.7 N/A Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -40.9 -32.8 N/A Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -24.1 -21.3 N/A Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -30.8 -25.7 N/A Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A -4,890.3 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.5 2.2 N/A Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -17.9 -57.3 N/A Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.4 31.2 N/A Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.4 31.2 N/A Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 63.0 88.4 N/A Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -540.9 -830.3 N/A Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.0 -14.9 N/A Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.1 -16.7 N/A Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 N/A Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -22.1 -16.7 N/A Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 243,333.3 44,512.2 N/A Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -243,333.3 -44,512.2 N/A Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ATX Shortsell

Frequently Asked Questions

The current share price of Amplia Therapeutics Ltd. (ATX:ASX) is AU$0.068.
The 52-week high share price for Amplia Therapeutics Ltd. (ATX:ASX) is AU$0.12.
The 52-week low share price for Amplia Therapeutics Ltd. (ATX:ASX)? is AU$0.06.
Amplia Therapeutics Ltd. (ATX:ASX) does not pay a dividend.
Amplia Therapeutics Ltd. (ATX:ASX) does not pay a dividend.
Amplia Therapeutics Ltd. (ATX:ASX) has a franking level of 0%.
Amplia Therapeutics Ltd. (ATX:ASX) is classified in the Healthcare.
The current P/E ratio for Amplia Therapeutics Ltd. (ATX:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.